trim estim pt
reduc annual ep estim reflect
launch delay investor also reduc pt
maintain equal-weight rate await
greater clariti growth prospect
lower annual estim primarili due delay gproair lower
ep estim reflect delay launch gproair assum launch
oct instead oct lower revenu project
also lower ep project follow
overal compound-annual-growth-rate remain unchang revenue
ep note futur tuck-in deal could boost financi
project new vs old vs consensu estim management indic
gproair launch delay would lower revenu guidanc
ep base convers compani
understand revenu impact account inventori
stock disclos assum full quarter sale eg
launch octob
also reduc due expect flattish gener rx segment
perform cut revenue ep
manag convey recent investor confer
expect busi segment deliv flattish sequenti sale next
quarter acceler due new product launch recal
experienc suppli disrupt scopolamin basic
market sinc start year management state rx guidanc
reflect relaunch product regard gproair launch delay
sale expect rx segment come may guidanc
subtract gproair sale result expect low
percentag adjust net sale rx segment prior
gproair delay current model rx gener sale
contribut full year segment sale separ see
recent note highlight management commentari
reduc pt cut pt ep
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
ep lower price-to-earnings target given gproair launch
uncertainti lack clariti regard compani growth prospect target
price-to-earnings discount mean premium vs gener group mean
ep due busi mix less leverag risk reward look
forward manag provid color valu creation
roadmap capit alloc plan fall
expans due cost cut solid
revenue ep
price target base ep target
price-to-earnings discount mean premium vs gener
specialti pharma group mean ep due busi mix less
pipelin drive earn upsid multipl expans new launch drive
ep multipl increas consum segment perform better
deliv result line expect growth prospect
remain cloudi manag execut well improv chci
segment perform return modest growth rel
new launch disappoint pressur worsen us consum rx declin
new launch delay competit pressur worsen ep
north american store-brand
counter medicin adj op incom
intern consum over-the-counter adj
op incom franchis omega
management work turn around
nich prescript rx gener
adj op incom leader gener topic
limit competit gener nich
quarterli result guidanc updat
us privat label over-the-counter gener rx launch
gproair launch
futur divestitur
risk achiev price
new product launch delay
exhibit us spec brand gx comp sheet
us specialti brand gener
spec brand gx mean
spec brand gx median
price
price
valuat methodolog risk associ price target rate
recommend referenc research report pleas contact client support
follow us/canada hong kong latin
sydney tokyo altern may contact
invest repres morgan stanley research broadway attent
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
